Seeta Eye Centers, Poughkeepsie, New York.
Lehmann Eye Center, Nacogdoches, Texas.
Ophthalmology. 2021 Feb;128(2):197-207. doi: 10.1016/j.ophtha.2020.07.015. Epub 2020 Sep 28.
To evaluate the effectiveness and safety of a trifocal intraocular lens (IOL), the TFNT00 (Alcon, Fort Worth, TX), versus a monofocal IOL, the SN60AT (Alcon).
Food and Drug Administration-approved, prospective, multicenter, nonrandomized, parallel-group, assessor-masked, confirmatory trial.
Patients enrolled were 22 years of age or older with a diagnosis of bilateral cataract with planned removal by phacoemulsification with a clear corneal incision.
Consented participants selected their preferred IOL, which was implanted sequentially into each eye of patients meeting eligibility criteria.
The coprimary effectiveness outcomes were mean photopic monocular best-corrected distance visual acuity (BCDVA; 4 m) and distance-corrected near visual acuity (DCNVA; 40 cm) at 6 months after surgery. Secondary effectiveness outcomes included mean monocular distance-corrected intermediate visual acuity (DCIVA; 66 cm) and proportion of participants responding "never" to question 1 of the Intraocular Lens Satisfaction questionnaire (regarding frequency of spectacle use in the past 7 days). Safety outcomes included frequency of "severe" and "most bothersome" visual disturbances.
Two hundred forty-three patients underwent cataract surgery with bilateral implantation of the TFNT00 (n = 129) or SN60AT (n = 114) and were followed up for 6 months. Noninferiority of TFNT00 to SN60AT in mean photopic monocular BCDVA (95% upper confidence limit of the difference was <0.1 logarithm of the minimum angle of resolution [logMAR] margin), and superiority in mean photopic monocular DCNVA (difference of 0.42 logMAR; P < 0.001) and DCIVA (difference of 0.26 logMAR; P < 0.001) were demonstrated. The proportion of patients never requiring glasses overall was superior for TFNT00 versus SN60AT (80.5% and 8.2%, respectively). Starbursts, halos, and glare were the most frequently rated severe symptoms with TFNT00; however, less than 5% of patients were very bothered at month 6.
The TFNT00 exhibited superior monocular DCNVA and DCIVA to a spherical monofocal IOL, with comparable monocular BCDVA. Binocular visual acuity was 20/25 or better for distance to near (+0.5 D to -2.5 D), resulting in high levels of spectacle independence. Less than 5% of patients were very bothered by the photic visual disturbances associated with the TFNT00 at 6 months after surgery.
评估三焦点人工晶状体(IOL)TFNT00(爱尔康,沃斯堡,德克萨斯州)与单焦点 IOL SN60AT 的有效性和安全性。
食品和药物管理局批准的、前瞻性的、多中心、非随机、平行组、评估者盲法、确证性试验。
年龄在 22 岁或以上、有双侧白内障诊断且计划通过超声乳化白内障吸除术联合透明角膜切口进行治疗的患者。
同意参加的患者选择了他们首选的 IOL,该 IOL 被依次植入符合入选标准的患者的每只眼中。
主要疗效终点是术后 6 个月时平均明视单眼最佳矫正远视力(BCDVA;4 m)和远距矫正近视力(DCNVA;40 cm)。次要疗效终点包括平均单眼远距矫正中间视力(DCIVA;66 cm)和对“过去 7 天内是否经常需要戴眼镜”问题 1 的 Intraocular Lens Satisfaction 问卷的回答比例(从不需要)。安全性终点包括“严重”和“最困扰”视觉障碍的发生率。
243 名患者接受了双侧白内障手术,分别植入 TFNT00(n=129)或 SN60AT(n=114),并随访 6 个月。TFNT00 在平均明视单眼 BCDVA 方面不劣于 SN60AT(差异的 95%置信上限小于 0.1 最小角分辨率对数 [logMAR] 差值),且在平均明视单眼 DCNVA(差值 0.42 logMAR;P < 0.001)和 DCIVA(差值 0.26 logMAR;P < 0.001)方面具有优越性。总的来说,TFNT00 组不需要戴眼镜的患者比例优于 SN60AT 组(分别为 80.5%和 8.2%)。TFNT00 最常报告的严重症状是星爆、晕影和眩光;然而,6 个月时,不到 5%的患者感到非常困扰。
与球面单焦点 IOL 相比,TFNT00 显示出优越的单眼 DCNVA 和 DCIVA,同时具有相似的单眼 BCDVA。双眼视力在距离到近(+0.5 D 至-2.5 D)为 20/25 或更好,导致高度的眼镜独立性。术后 6 个月时,不到 5%的患者对与 TFNT00 相关的光觉干扰感到非常困扰。